secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001493152-23-039902
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma reports Q3 net loss $6.1M; FDA supports MAT2203 Phase 3 with LPAD pathway
--------------------------------------------------------------------------------

- Net loss of $6.1M ($0.03 per share) in Q3 2023 vs $5.5M in Q3 2022; no revenue vs $1.1M from BioNTech in prior year.
- Cash $18.2M at Sep 30, 2023; runway into Q3 2024; seeking non-dilutive BARDA funding.
- FDA agreed MAT2203 Phase 3 design for invasive aspergillosis with limited treatment options; acknowledged LPAD registration pathway.
- FDA open to superiority composite endpoint to strengthen commercial positioning without increasing study size (<200 patients).
- Patient with Candida krusei achieved complete clinical resolution after 2 weeks on MAT2203; new fusarium patient enrolled at Vanderbilt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223039902/0001493152-23-039902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223039902/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer